Iverson Ann M, Arbuckle Amanda L, Song David Y, Bihun Emily C, Black Kevin J
Washington University School of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA.
Department of Psychiatry, Washington University in St. Louis, St. Louis, MO 63110, USA.
J Clin Med. 2023 Mar 28;12(7):2545. doi: 10.3390/jcm12072545.
Median nerve stimulation (MNS) at 10-12 Hz was recently proposed as a treatment for Tourette syndrome and other chronic tic disorders (TS/CTD). We report on 31 participants ages 15-64 with TS/CTD in an open-label, comparative (within-group, several time points) study of MNS (ClinicalTrials.gov registration number NCT05016765). Participants were recruited from completers of a randomized controlled trial (RCT) of MNS and were given a transcutaneous electrical nerve stimulation (TENS) unit to use as desired for 12 Hz MNS for 4 weeks. Participants were instructed to complete surveys regarding tic symptoms and stimulation discomfort before and after stimulation, as well as twice daily when randomly prompted by text message. Participants also completed an extensive final survey. Twenty-seven participants completed the study. Median device use was 1.5 days per week and 50 min per day used. Tic frequency improved during MNS (mean improvement: 1.0 on a 0-5 scale, < 0.001), as did tic intensity (mean improvement: 0.9, < 0.001). Mean discomfort was mild (1.2 on a 3-point scale). In total, 21 participants (78%) planned to continue using the device. Participants' results in this study did not correlate significantly with their results in the blinded RCT. We found MNS to improve tic frequency and intensity with minimal side effects.
最近有人提出，以10 - 12赫兹的频率进行正中神经刺激（MNS）可用于治疗抽动秽语综合征和其他慢性抽动障碍（TS/CTD）。我们报告了一项针对31名年龄在15 - 64岁之间的TS/CTD患者的开放性、对比性（组内，多个时间点）MNS研究（ClinicalTrials.gov注册号NCT05016765）。参与者从MNS随机对照试验（RCT）的完成者中招募，并获得一个经皮电神经刺激（TENS）装置，可根据需要用于12赫兹的MNS，为期4周。参与者被要求在刺激前后以及每天随机收到短信提示时两次完成关于抽动症状和刺激不适的调查。参与者还完成了一项广泛的最终调查。27名参与者完成了研究。装置使用的中位数为每周1.5天，每天使用50分钟。在MNS期间，抽动频率有所改善（平均改善：在0 - 5分的量表上为1.0，<0.001），抽动强度也有所改善（平均改善：0.9，<0.001）。平均不适感较轻（在3分制量表上为1.2）。总共有21名参与者（78%）计划继续使用该装置。参与者在本研究中的结果与他们在盲法RCT中的结果没有显著相关性。我们发现MNS能改善抽动频率和强度，且副作用最小。
